| Cheng Hsin-Chung |
------>authors3_c=None ------>paper_class1=2 ------>Impact_Factor=None ------>paper_class3=0 ------>paper_class2=0 ------>vol= ------>confirm_bywho=jackson ------>insert_bywho=g4808 ------>Jurnal_Rank=None ------>authors4_c=None ------>comm_author= ------>patent_EDate=None ------>authors5_c=None ------>publish_day=None ------>paper_class2Letter=None ------>page2=117 ------>medlineContent= ------>unit=F0100 ------>insert_date=20000603 ------>iam=1 ------>update_date= ------>author=??? ------>change_event=5 ------>ISSN=None ------>authors_c=None ------>score=-37 ------>journal_name=Abstracts Book of 2nd Asia-Pacific Travel Health Congress ------>paper_name=Common oral diseases during travel ------>confirm_date=20000615 ------>tch_id=083027 ------>pmid=17437472 ------>page1=117 ------>fullAbstract=BACKGROUND: Acute mountain sickness (AMS) affects almost half of those ascending to heights over 3,000 m. The knowledge and practices concerning AMS have not been adequately studied. METHODS: We conducted a prospective on-site study in the Himalayas. Between July and October 2004, we approached a convenience sample of trekkers during or after their ascent to high altitudes and provided them with detailed questionnaires regarding knowledge of and personal experience with AMS. RESULTS: One hundred ninety-two travelers (of whom 106 were Israelis and 86 Western Europeans) participated in the study. One hundred thirty travelers (68%) had received any written/oral information about AMS prior to their departure. The most common source of information among Israeli travelers was the travel clinic (65%), compared to only 9% among Europeans. Overall, 89% were found to have good "basic knowledge" about symptoms of AMS (defined as headache plus > or =2 of the following: fatigue, dizziness, nausea, insomnia). Travelers who had received information about AMS prior to their trip were significantly more knowledgeable about symptoms of AMS (p= 0.0001), and treatment options, such as oxygen, medications, and rest (p= 0.023, p= 0.024, p= 0.011, respectively). Only 2% of the Israelis versus 16% of the Europeans (p= 0.0004) knew that O(2) was a treatment option. Forty-seven percent suffered from AMS, which in 50% began at 3,000 m. About 33 of 90 (37%) of those who suffered AMS symptoms had acetazolamide with them, but only 14 actually used it as treatment. CONCLUSIONS: Knowledge of AMS among climbers to high altitudes should be fostered, with specific emphasis on practical advice. ------>tmu_sno=None ------>sno=1702 ------>authors2=None ------>authors3=None ------>authors4=None ------>authors5=None ------>authors6=None ------>authors6_c=None ------>authors=Cheng Hsin-Chung ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c=None ------>publish_area=None ------>updateTitle=Are we doing our best to educate travelers about the risks of acute mountain sickness? An on-site prospective study in the Himalayas. ------>language=2 ------>check_flag= ------>submit_date= ------>country=None ------>no= ------>patent_SDate=None ------>update_bywho= ------>publish_year=1998 ------>submit_flag= ------>publish_month=None |